For instance, as IL-6 is the key driver of the inflammatory state associated with COVID-19, therapeutic approaches targeting IL-6 have attracted high levels of interest, for example, antibodies that specifically block IL-6 receptors and are approved by FDA (e.g., tocilizumab and sarilumab) are under clinical trials [146]. This evidence concerns the gene IL6 and COVID-19.